Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chitra Hosing

Showing results (151-160 of 234) with videos related to

Pageof 24
Sort By:
Leukemia & Lymphoma|July 5, 2017
A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single centerGhulam Rehman Mohyuddin, Muhammad Salman Faisal, Talha Badar, et al.
Bone Marrow Transplantation|June 17, 2026
Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCyYosra M Aljawai, Kai Cao, Jun Zou, et al.
Blood Advances|January 24, 2024
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantationCurtis Marcoux, Rima M Saliba, Whitney Wallis, et al.
Transplantation and Cellular Therapy|August 22, 2023
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell LymphomaHanan Alkhaldi, Alec Reinhardt, Melissa Barnett, et al.
Blood Immunology & Cellular Therapy|July 8, 2026
Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CARTKunhwa Kim, Zachary Hunzeker, Xiaowen Sun, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2011
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of lifeGheath Alatrash, Marcos de Lima, Nelson Hamerschlak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 11, 2015
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological MalignanciesAmin M Alousi, Jonathan E Brammer, Rima M Saliba, et al.
Advances in Radiation Oncology|October 30, 2018
Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapyTommy Sheu, Sarah A Milgrom, Therese Y Andraos, et al.
Cancer|May 18, 2017
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myelomaLauren W Veltri, Denái R Milton, Ruby Delgado, et al.
Haematologica|April 7, 2018
A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphomaPaolo Strati, Dai Chihara, Yasuhiro Oki, et al.
Pageof 24

Showing results (151-160 of 234) with videos related to

Sort By:
Pageof 24
Leukemia & Lymphoma|July 5, 2017
A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single centerGhulam Rehman Mohyuddin, Muhammad Salman Faisal, Talha Badar, et al.
Bone Marrow Transplantation|June 17, 2026
Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCyYosra M Aljawai, Kai Cao, Jun Zou, et al.
Blood Advances|January 24, 2024
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantationCurtis Marcoux, Rima M Saliba, Whitney Wallis, et al.
Transplantation and Cellular Therapy|August 22, 2023
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell LymphomaHanan Alkhaldi, Alec Reinhardt, Melissa Barnett, et al.
Blood Immunology & Cellular Therapy|July 8, 2026
Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CARTKunhwa Kim, Zachary Hunzeker, Xiaowen Sun, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2011
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of lifeGheath Alatrash, Marcos de Lima, Nelson Hamerschlak, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 11, 2015
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological MalignanciesAmin M Alousi, Jonathan E Brammer, Rima M Saliba, et al.
Advances in Radiation Oncology|October 30, 2018
Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapyTommy Sheu, Sarah A Milgrom, Therese Y Andraos, et al.
Cancer|May 18, 2017
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myelomaLauren W Veltri, Denái R Milton, Ruby Delgado, et al.
Haematologica|April 7, 2018
A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphomaPaolo Strati, Dai Chihara, Yasuhiro Oki, et al.
Pageof 24